by CRISPR & Cas Genes Market size is expected to grow Usd 4.23 bn by 2027 at a CAGR of 16.02% over the forecast period 2020 – 2027.
A new study on the global CRISPR & Cas Genes market has been published by Precedence Research. It presents a wealth of information on key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the global CRISPR & Cas Genes market. The study offers valuable information about the global CRISPR & Cas Genes market to illustrate how the market would grow during the forecast period 2020-2027. The report provides the value and volume of the global CRISPR & Cas Genes market for the period 2020–2027, considering 2019 as the base year and 2027 as the forecast year. The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study.
Key indicators of market growth, which include value chain as well as supply chain analyses, and Compound Annual Growth Rate (CAGR), are elucidated in the study in a comprehensive manner. This data can help readers interpret quantitative growth aspects of the global CRISPR & Cas Genes market during the forecast period.
Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1108
An extensive analysis on business strategies of leading market players is also featured in study on the global CRISPR & Cas Genes market. This can help readers understand principal factors to foresee growth in the global CRISPR & Cas Genes market. In this study, readers can also find specific data on the qualitative and quantitative growth avenues for the global market, which is expected to guide market players in making apt decisions in the future.
The report also delves into the competition landscape of the global CRISPR & Cas Genes market. Key players operating in the global market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global market report.
Key Players
- Caribou Biosciences, Inc.
- F. Hoffmann-La Roche Ltd.
- Cellectis
- AstraZeneca
- Editas Medicine, Inc.
- Addgene
- Egenesis
- Horizon Discovery Group Plc
- Intellia Therapeutics, Inc.
- Genscrip
- Danaher Corporation
- Lonza
- Merck KGaA
- Synthego
- Mammoth Biosciences
- Inscripta, Inc.
- Cibus
- New England BioLabs
- Takara Bio, Inc.
Key Questions Answered in CRISPR & Cas Genes Market Study
– What are the key factors influencing the CRISPR & Cas Genes market in each region?
– What will be the CAGR of the global CRISPR & Cas Genes market between 2016 and 2027?
– What is the future scope and changing trends in technologies in the global CRISPR & Cas Genes market?
– Which factors will impede the growth of the global CRISPR & Cas Genes market during the forecast period?
– Which are the leading companies in the global CRISPR & Cas Genes market?
– Which region is set to expand at the fastest CAGR during the forecast period?
– What is the volume (Units) of different CRISPR & Cas Genes across all regions during the forecast period?
– Which segment will have the highest revenue globally in 2027 and which segment will expand at the fastest CAGR during the forecast period?
Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1108
Research Methodology
A unique research methodology has been utilized by precedence research to conduct a comprehensive research on the growth of the global CRISPR & Cas Genes market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary sources referred to by analysts during the production of the global CRISPR & Cas Genes market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from CRISPR & Cas Genes industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped in making precedence research estimates on the future prospects of the global market more reliable and accurate.
Segmentation
By Product & Service
- By Service
- Microbial Gene Editing
- Cell Line Engineering
- gRNA Design
- DNA Synthesis
- By Product
- Design Tool
- Kits & Enzymes
- Libraries
- Antibodies
- Others
By Application
- Agricultural
- Biomedical
- Functional Genomics
- Genome Engineering
- Disease Model Studies
- Epigenetics
- Others
- End-use Outlook
- Contract Research Organizations (CROs),
- Academics & Government Research Institutes
- Biotechnology & Pharmaceutical Companies
By Regional Outlook
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Middle East & Africa
- Latin America
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global CRISPR & Cas Genes Market, By Product & Service
7.1. CRISPR & Cas Genes Market, by Product & Service Type, 2020-2027
7.1.1. Service
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Product
7.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global CRISPR & Cas Genes Market, By Application
8.1. CRISPR & Cas Genes Market, by Application, 2020-2027
8.1.1. Agricultural
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Biomedical
8.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global CRISPR & Cas Genes Market, By End-Use
9.1. CRISPR & Cas Genes Market, by End-Use, 2020-2027
9.1.1. Contract Research Organizations (CROs)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Academics & Government Research Institutes
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Biotechnology & Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 10. Global CRISPR & Cas Genes Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
Chapter 11. Company Profiles
11.1. Caribou Biosciences, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. F. Hoffmann-La Roche Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cellectis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Editas Medicine, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Addgene
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Egenesis
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Horizon Discovery Group Plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Intellia Therapeutics, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Genscrip
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Danaher Corporation
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Lonza
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Merck KGaA
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. Synthego
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. Mammoth Biosciences
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
11.16. Inscripta, Inc.
11.16.1. Company Overview
11.16.2. Product Offerings
11.16.3. Financial Performance
11.16.4. Recent Initiatives
11.17. Cibus
11.17.1. Company Overview
11.17.2. Product Offerings
11.17.3. Financial Performance
11.17.4. Recent Initiatives
11.18. New England BioLabs
11.18.1. Company Overview
11.18.2. Product Offerings
11.18.3. Financial Performance
11.18.4. Recent Initiatives
11.19. Takara Bio, Inc.
11.19.1. Company Overview
11.19.2. Product Offerings
11.19.3. Financial Performance
11.19.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Get Full Access of this Research Report, Click here@ https://www.precedenceresearch.com/checkout/1108
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
